DCUK OEt
Alternative Names: DCUK-OEt; NezavistLatest Information Update: 10 Oct 2025
At a glance
- Originator Lohocla Research
- Class Antidepressants; Drug withdrawal therapies; Small molecules
- Mechanism of Action GABA receptor agonists; Glutamate antagonists; NMDA receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alcoholism
- Preclinical Depressive disorders
Most Recent Events
- 28 Feb 2025 Phase-I clinical trials in Alcoholism (In volunteers) in USA (PO) (NCT06633562)
- 20 Jan 2025 Nezavist is still in preclinical development in Alcoholism in USA, preclinical development in Depressive disorders in USA (Lohocla Research pipeline, January 2025)
- 09 Oct 2024 Lohocla Research Corporation plans a phase I trial (In volunteers) in USA (PO) in January 2025 (NCT06633562)